Vistagen (NASDAQ: VTGN) received a "Study May Proceed" letter from the U.S. Food and Drug Administration for its refisolone nasal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE